9 jan 2023
JPMorgan presentation
Potential for indication expansion: Literature reports of CAIX expression
Glioblastoma Multiforme
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma
Gastric Cancer
Pancreatic Ductal Adenocarcinoma
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Cancer
Small Cell Lung Cancer
Cholangio-carcinoma
Soft Tissue Sarcoma
Epithelial Ovarian Cancer
Colorectal Cancer
- Forums
- ASX - By Stock
- Ann: Phase II study for indication expansion of TLX250-CDx doses
9 jan 2023JPMorgan presentationPotential for indication...
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$18.15 |
Change
0.600(3.42%) |
Mkt cap ! $6.073B |
Open | High | Low | Value | Volume |
$17.80 | $18.15 | $17.63 | $14.74M | 822.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1200 | $18.12 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.18 | 3850 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1200 | 18.120 |
1 | 1696 | 18.090 |
1 | 450 | 18.080 |
2 | 1250 | 18.020 |
2 | 2000 | 18.010 |
Price($) | Vol. | No. |
---|---|---|
18.180 | 3850 | 4 |
18.190 | 5759 | 2 |
18.200 | 50 | 1 |
18.220 | 4759 | 1 |
18.260 | 4759 | 1 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |